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A B S T R A C T
The incidence of diabetes mellitus, as well as its complications, is rapidly growing. Diabetic nephropathy is one
of the most prevalent disorders induced by chronic uncontrolled hyperglycemia and is accompanied by a re-
duction in renal sufficiency with microstructural tissue damage in the kidneys. Many therapeutic protocols have
been designed to address the treatment and prevention of diabetic nephropathy. Sodium-glucose co-transporter
2 inhibitors (SGLT2i) are a newly introduced class of glucose-lowering agents that reduce blood glucose by
inhibition of urinary glucose reabsorption in renal proximal tubules and so induce glycosuria. Also, these hy-
poglycemic agents may provide protective effects in different tissues such as cardiovascular, brain, and kidneys.
In recent years, accumulating evidence has indicated that SGLT2i possess potent renal protective properties in
the setting of diabetes. In the current study, we present the latest findings regarding the renoprotective effects of
SGLT2 inhibition and discuss the molecular mechanisms involved.
1. Introduction
The global prevalence of diabetes mellitus (DM) is burgeoning [1].
This metabolic disorder involves disordered metabolism leading to ac-
tivation of pathologic molecular pathways such as oxidative stress, in-
flammation and apoptosis [2,3]. Therefore, diabetes impacts most tis-
sues producing undesirable diabetic complications [4,5]. Diabetic
nephropathy (DN) is prevalent among diabetic patients and is activated
by underlying molecular mechanisms induced by uncontrolled hy-
perglycemia [6]. DN is also the most prevalent cause of renal failure
(from which up to 30% of diabetic patients will suffer) and leads to the
need for renal replacement therapy [7,8]. The exact pathophysiology of
DN is as yet unclear, but the roles of oxidative damage, inflammatory
responses and apoptosis are well recognized [9]. Together with dia-
betes-induced cardiovascular complications, DN is considered to be the
major cause of mortality in patients with uncontrolled diabetes [10].
Hence, many preventive or therapeutic strategies have been developed
to improve renal sufficiency in diabetic patients [4,11].
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are a
newly introduced class of antidiabetic agents which reduce plasma
glucose by inhibition of glucose uptake in renal proximal tubules
[12–15]. Sodium-glucose cotransporters are mainly located in the brush
border of renal proximal tubules and are responsible for re-uptake of
filtrated glucose from tubules and returning it to the circulation [12].
Thus, inhibition of these carriers translates into urinary glucose excre-
tion and lower levels of plasma glucose [12]. Therefore, SGLT2i can
induce a potent glucose-lowering effect, especially in patients with
higher prevailing levels of glycaemia [12]. However, some evidence
indicates that these agents can also provide other therapeutic effects,
specifically on the kidneys [12]. SGLT2i drugs have been shown to be
able to suppress the molecular mechanisms involved in the pathophy-
siology of DN [8,12]. In the current review, we present the latest
findings regarding the renoprotective effects of SGLT2 inhibition and
discuss the molecular mechanisms involved.
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2. Classification of diabetes mellitus
DM has been traditionally categorized into three main types as type
1 diabetes (T1D), type 2 diabetes (T2D) and gestational diabetes [16].
Nonetheless, a novel diabetes classification (based on glutamate dec-
arboxylase antibodies, age at diagnosis, body mass index, HbA1c, in-
sulin resistance, and β-cell function) has recently been proposed in-
cluding 5 subgroups: severe autoimmune diabetes, severe insulin-
deficient diabetes, severe insulin-resistant diabetes, mild obesity-re-
lated diabetes and mild age-related diabetes [17]. T1D accounts for
approximately 5–10% of all diabetic subjects and is due to auto-
immune-mediated beta-cell destruction resulting in insufficient insulin
production from residual beta cells and low circulating insulin levels
[16]. T2D is the most prevalent type of diabetes, accounting for
90–95% of diabetic subjects, and is due to inadequate insulin secretion
combined with insulin resistance [16]. Gestational diabetes is another
type of DM which develops in pregnant women, usually resolves post-
delivery, and is due largely to hormonal variations during pregnancy
[18]. Severe autoimmune diabetes overlap with T1D and latent auto-
immune diabetes in adults (LADA), severe insulin-deficient diabetes
and severe insulin-resistant diabetes (SIRD) are two severe forms of
T2D accounting for 10–20% and 10–17% of diabetic subjects respec-
tively, while the most prevalent subgroup is mild-age-related diabetes
(35–47%) [17]. The risk of DN is particularly increased in the SIRD
subgroup, thus highlighting a major role of insulin resistance in diabetic
kidney diseases.
3. Pathophysiology of diabetic nephropathy at a glance
DN has a complicated pathophysiology [19,20]. Although its exact
underlying cause is still unclear, activation of many molecular path-
ways is involved; these include oxidative stress [3], endoplasmic re-
ticulum stress [21], glomerular hyperfiltration [22], inflammation [23],
innate immunity [24], the renin-angiotensin system (RAS) [25],
transforming growth factor-β (TGF-β) [26], protein kinase C (PKC)
[25], tumor necrosis factor-α (TNF-α) [25], nuclear factor kappa-b (NF-
κb) [27], adhesion molecule up-regulation [28], and apoptotic path-
ways [9]. Hemodynamic variation and intraglomerular hypertension
are additionally responsible for the renal tissue injuries induced by
chronic uncontrolled hyperglycemia [29]. Insulin resistance is asso-
ciated with many of these mechanisms, such as glomerular hyperten-
sion, hyperfiltration, and inflammation [30]. Accordingly, the pre-
valence of DN has been reported to be high in the SIRD cluster of
patients, with severe insulin resistance [20]. Those patients showed
overall an adequate metabolic control, thus suggesting that other than
hypoglycemic mechanisms are required for renoprotection [17].
4. SGLT2 inhibitors
SGLT2 inhibitors are a group of glucose lowering drugs that inhibit
glucose tubular reabsorption and induce its urinary excretion by re-
duction of the renal glucose threshold [12,31]. This class of hypogly-
cemic drugs works completely independent of the insulin hormone and
functions according to the prevailing serum glucose level, thereby
carrying a negligible risk for hypoglycemia [32]. After the discovery of
phlorizin as the first SGLT inhibitor, several formulations of SGLT2
inhibitor have been introduced [32,33]. These antidiabetic agents re-
duce plasma glucose by decreasing renal tubular glucose reabsorption
[34,35]. In addition to their potent hypoglycemic effects, they may also
exert other effects, such as weight loss [36], decreased blood pressure
[37], reduced uric acid levels [38], attenuation of oxidative stress [39],
anti-inflammatory action [40], and improve fibrosis [40], SGLT2 in-
hibitors may, however, be accompanied by side effects, such as dehy-
dration, dizziness and fainting, hypotension and urinary tract infections
[41]. Canagliflozin, dapagliflozin, and empagliflozin are approved
SGLT2i in widespread clinical use [41].
5. Renoprotective effects of SGLT2 inhibition
Although hypoglycemic effects are the initial outcomes of SGLT2i,
emerging evidence suggests that these antidiabetic drugs exhibit other
pharmacological properties with effective renoprotective effects [42].
These beneficial activities of SGLT2i on renal outcomes may be due to
their glucose lowering mechanisms while other renoprotective effects
could be independent of them; however, it is not fully understood yet
and further detailed studies are needed in this field to elucidate whether
the renal protection of SGLT2i is solely explained by their anti-
hyperglycemic effects or not. In this regard, it has been well demon-
strated that SGLT2i protect kidneys by anti-inflammatory effects via
reducing serum levels of leptin and IL-6, increasing adiponectin con-
centrations, mitigating systemic inflammation through decreasing CRP
(C-reactive protein) level, and inhibition the IL-1β secretion by mac-
rophages via the ROS-NLRP3-caspase-1 pathway [43–45]. It seems that
these anti-inflammatory effects of SGLT2i as well as some other me-
chanisms such as lowering serum uric acid levels, blood pressure, and
glomerular hyperfiltration are independent of their glucose-lowering
properties. However, the evidence suggests that these antidiabetic
drugs may be considered as both renoprotective and hypoglycemic
agents. In this review, we discuss about the possible molecular me-
chanisms involved in the renoprotective actions of SGLT2i (Table 1).
5.1. Improvement of glycemic control
Hyperglycemia is the most prominent and obvious issue in diabetes,
and many subsequent complications are due to elevated serum glucose
Table 1
Major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors.
Mechanisms Role of SGLT2 Inhibition Ref.
Renoprotective roles of SGLT2
inhibitors
Improvement of Glycemic Control Reduction in blood glucose and thereby prevention of
glucotoxicity
[8,49,50,51,53]
Improvement of Hemodynamic Variations Prevention of hemodynamic changes, readjustment of blood
pressure control
[8,52,60,61,62,66,70]
Induction of Weight Loss Reduction in body weight and prevention of obesity-related
complications
[8,70,73,74]
Prevent of Oxidative Damages Amelioration of free radical generation and prevention of
downstream consequences including apoptosis
[12,76,77] [78,79,82,83]
Inhibition of Inflammatory Responses and
Fibrotic Processes
Attenuation of inflammatory mediator expression/release,
prevention of fibrosis in kidney tissues
[12,93,94,95]
Reduction of Uric Acid Levels in Plasma Induction of uric acid urinary excretion [96,100,101,102,103,104,105]
Reduction in RAS Activation Amelioration of RAS activity leading to decreased deleterious
outcomes.
[106,109,110]
Reduction in Natriuretic Peptides Regulation of natriuretic peptide secretion [117,121,122]
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concentrations [46,47]. Glucose is a potent inducer of many patho-
physiologic pathways, such as oxidative stress, inflammation and
apoptosis that are involved in DN and chronic kidney disease (CKD)
[2,3,48] (Fig. 1). Therefore, any glucose lowering agent can protect
against this "Diabetic Glucotoxicity" and, thereby, prevent hypergly-
cemia-induced disorders including CKDs [47]. This effect is common
across all classes of hypoglycemic drugs, but SGLT2i agents have been
proposed to play additional benefits on glucotoxicity in susceptible
tissues such as kidneys, the cardiovascular system and the neuronal
network [49–51]. In particular, SGLT2 ameliorated oxidative stress,
fibrosis and inflammation predominantly in the tubule-interstitium
[39,50] and showed a greater efficacy than dipeptidyl peptidase-4 in-
hibitors in improving hippocampal synaptic plasticity [51].
Aroor et al. in 2018 demonstrated that the hypoglycemic effects of
SGLT2i are critically important in reducing renal damage in T2D animal
model [52]. Fioretto and colleagues in 2016 reported that the re-
noprotective properties of SGLT2i are, at least in part, due to an im-
provement in the glycemic profile [8]. Of note, the hypoglycemic ef-
fects of SGLT2is are dependent upon normal kidney function and
normal physiological feedback between the renal macula densa and
glomerulus [8]. Therefore, SGLT2i may not be as effective in renal
failure where the eGFR (estimated glomerular filtration rate) is below
60mL/min/1.73 m2 [8,53]. Their action on glucose control is reduced
in patients with impaired renal function and their use might be ac-
companied by side effects [54]. Nevertheless, the beneficial effect of
SGLT2i on cardiovascular risk factors such as body weight, blood
pressure, and urinary albumin-to-creatinine ratio persists despite renal
impairment [55] resulting in renoprotection via non-glucosuric me-
chanisms. Additionally, because SGLT2is exhibit prominent non-
glycemic effects possibly via natriuretic/diuretic effects, inhibition of
sodium reabsorption in the proximal tubule and downregulation of
NHE3 sodium transport activity [55], these antidiabetic drugs could
exert their renoprotective activities in nondiabetic patients.
5.2. Reduction in tubular Na+reabsorption and improvement of
hemodynamic variations and blood pressure
Diabetes-induced microvascular complications, such as DN, are ac-
companied by hemodynamic variations and systemic hypertension and,
therefore, normalizing blood pressure (BP) is critical in the prevention
of CKD in diabetic patients [56,57]. Raised BP potentially reduces renal
sufficiency by induction of hyperfiltration and intraglumerular pres-
sure, leading to destruction of the glomerular network at the micro-
vascular level [58,59].
Emerging evidence shows that SGLT2 inhibition improves diastolic
and systolic BP control by lowering body weight and via induction of
osmotic diuresis that results in hypovolemia [8,60–62]. SGLT2 inhibi-
tion decreases sodium reabsorption in the proximal tubules, thereby
causing increased sodium delivery to the macula densa in the distal
tubule and inducing afferent vasoconstriction by tubuloglomerular
feedback leading to lower glomerular hyperfiltration [62,63]. Reduc-
tion in BP may also be linked to a decrease in total body sodium con-
tent. In this regard, it has been revealed that a significant reduction of
skin sodium content following SGLT2i therapy; nevertheless, it is not
clear whether the decreased sodium content is a direct effect of these
drugs or a consequence of prolonged reduction in renal sodium excre-
tion [64]. It has been hypothesized that SGLT2i may decrease inter-
stitial fluid volume suggesting a potential therapeutic effect in heart
failure by reducing congestion without decreasing arterial filling and
organ perfusion [65]. SGLT2i use also improves vascular stiffness re-
sulting in increased elasticity and more efficient BP regulation [52,66].
Furthermore, it has been reported that SGLT2is exhibit a slight acute
reduction in eGFR and lower albuminuria during treatment [67,68];
however, glomerular hemodynamic changes may be reversed after
discontinuation of SGLT2is [69]. Recent results of a large clinical trial
(CREDENCE) supported the potential benefits of SGLT2i on kidney and
cardiovascular outcomes in diabetic patients at a high risk for devel-
oping CKD [42]. SGLT2i used to manage diabetes also improve en-
dothelial function and prevent aortic stiffness by down-regulation of
RECK (“reversion inducing cysteine rich protein with Kazal motifs,” an
anti-fibrotic factor) through inhibition of membrane-anchored matrix
metalloproteinase activation resulting in a positive effect of SGLT2i on
periarterial fibrosis [52]. Lee et al in 2018 reported that SGLT2 in-
hibition improves systemic vascular dysfunction by reducing aortic
pulse wave velocity and increasing endothelium-dependent dilation
leading to decreased stiffness and an improved response to stimuli [66].
In summary, SGLT2 inhibition improves the hemodynamic deviations
that occur in CKDs and reduces BP by induction of osmotic diuresis and
improvement of endothelial function and vascular tone [52,66,70]. It is
noteworthy that these renoprotective effects of SGLT2i are likely in-
dependent to their glucose-lowering potencies.
5.3. Induction of weight loss and further consequences
Weight loss during treatment with SGLT2 inhibitors has been con-
sistently observed and it could be a consequence of the calorie deficit
induced by glycosuria [71]. A previous meta-analysis revealed that
different doses of each SGLT2i agent are associated with significant
weight reduction in T2D patients [72]. SGLT2 inhibition can be re-
noprotective through the reduction in body weight, since many pa-
thological molecular mechanisms involved in CKDs are influenced by
adipose tissue [8,70,73]. The SGLT2i-induced reduction in body weight
has also been linked to a decrease in triglyceride levels, leading to
improved insulin sensitivity [74]. Simply lowering body weight,
therefore, decreases the risk factors involved in the pathophysiology of
CKD and DN [74]. The weight loss effects of SGLT2i are notable
Fig. 1. Mechanisms implicated in tissue damage by chronic hyperglycemia.
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amongst anti-diabetic drugs, since many hypoglycemic agents are as-
sociated with weight gain and a higher risk of cardio-renal disorders
[74].
5.4. Prevention of oxidative damage
Oxidative stress is closely linked to the pathophysiology of CKDs
and DN [19]. Oxidative stress develops when the production of free
radical species is increased above physiological levels and overcomes
the capacity of the anti-oxidant defense system [75]. As a result, the
excess free radicals cause damage to various biological elements
[19,75]. Previously, we suggested that oxidative stress induces renal
failure by at least nine pathological molecular pathways including
modulation of transcription factors, induction of inflammatory re-
sponses, enhancement of advanced glycation end product (AGE) and
receptor for advanced glycation end product (RAGE) production, up-
regulation of protein kinase C (PKC), activation of various molecular
mechanisms (such as the hexosamine pathway, the polyol pathway, the
autonomic nerve system and the RAS) and, finally, via direct damage to
intracellular molecules [19].
SGLT2 inhibition exhibits potent anti-oxidative properties [12,76].
We illustrated previously that SGLT2 inhibitors can prevent oxidative
damage via reduction of free radical generation by several pathways
[12]. Reported evidence has confirmed that SGLT2is can suppress
oxidative stress in various tissues, including the kidneys [77]. Tang et al
in 2017 showed that dapagliflozin slows DN progression by down-
regulation of free radical progenitors such as Nox4 (nicotinamide
adenine dinucleotide phosphate oxidase (NADPH oxidase) 4, Nox2, and
the p47phox subunit of Nox4, and urinary excretion of TBARS (Thio-
barbituric acid reactive substances, a marker of lipid peroxidation)
[77]. Tanaka et al in 2018 reported that treatment with ipragliflozin
normalized glucose metabolism and re-adjusted the oxidative balance
in kidneys of diabetic animals [78]. Osorio et al in 2012 found that
SGLT2 inhibition using phlorizin prevented oxidative stress by pro-
motion of catalase (CAT) and glutathione peroxidase (GPX) activity and
reduced nitrogen free radicals in diabetic rats [79]. Ojima et al. in 2015
revealed that empagliflozin may, at least in part, inhibit oxidative stress
in DN via suppression of the AGE-RAGE axis [80]. It has also been
shown that empagliflozin reduces oxidative stress through induction of
Nrf2 translocation to the nucleus and activation of Nrf2/ARE signaling
in T2D model [81]. In conclusion, the antioxidative properties are an-
other beneficial effect of SGLT2 inhibition for prevention of CKD de-
velopment [82,83].
5.5. Inhibition of inflammatory responses and fibrotic processes
Inflammatory responses and fibrotic processes are observed in most
cases of CKD [77,84]. Progression of CKD is accompanied by higher
circulating levels of inflammatory mediators (together with their in-
creased expression and release) and increasing fibrosis [9,83–85]. Re-
cent evidence suggests inflammatory mediators as new therapeutic
targets for improvement of renal function in the setting of diabetes
[86–88]. Many inflammatory cytokines, including IL (interleukin)-1, IL-
6, IL-18, TNF-α, ICAM (intracellular cell adhesion molecules), VCAM
(vascular cell adhesion molecules), and MCP-1 (monocyte chemoat-
tractant protein-1), are involved in different aspects of renal injury and
are upregulated during uncontrolled hyperglycemia [7,86,89,90].
Moreover, some evidence has shown that increasing levels of in-
flammatory cytokines, such as IL-18, is closely linked to progression of
albuminuria [91]. Inflammatory responses and fibrotic processes in
renal proximal tubules are associated with higher TGF-β cytokine ex-
pression [73]. Liu et al in 2010 showed that proximal tubular cells
cultured in hyperglycemic conditions are accompanied by increased
inflammatory and profibrotic mediators [92]. Overall, the in-
flammatory hypothesis suggests that inflammatory mediators induce
renal tissue injuries, such as tubular apoptosis and interstitial fibrosis,
either directly or indirectly (via induction of other pathologic pathways
such as apoptosis) [7].
SGLT2i have anti-inflammatory effects by reducing serum leptin and
IL-6 levels and increasing adiponectin concentrations resulting in im-
proved adipose tissue function [44]{Yaribeygi, 2018 #11;Garvey WT,
2018 #21}. Besides, these antidiabetic drugs mitigate systemic in-
flammation through decreasing high-sensitivity C-reactive protein
concentrations and ameliorating insulin resistance [43]. Also, SGLT2is
exert an inhibitory effect on the secretion of IL-1β by macrophages via
the ROS-NLRP3-caspase-1 pathway [45]. These effects seem to be in-
dependent to glucose-lowering effects of SGLT2i. In a previous review
of experimental and clinical trial studies, we reported that SGLT2 in-
hibition, in the setting of diabetes, reduces inflammation via at least
five separate molecular pathways; namely, these include modulation of
the RAS activity, prevention of hemodynamic variations, reduction of
obesity–induced inflammation, alteration of the immune system and
readjustment of the redox state towards the normal condition [12].
SGLT2 inhibition may also improve adipose tissue function and regulate
serum levels of leptin and adiponectins, leading to reduced tissue in-
flammation [93]. It has suggested that SGLT2is ameliorate systemic low
grade inflammation as well as local tissue inflammation [93].
Panchapakesan et al in 2013 demonstrated that treatment by em-
pagliflozin in human proximal tubular cells caused a reduction in hy-
perglycemia-dependent TLR (Toll-like receptor) 2 and 4 and NF-κb
expression, leading to a reduction in inflammation and fibrosis [94].
Terami et al in 2014 found that dapagliflozin treatment in diabetic
animals reduced MCP-1, ICAM-1 and TGF-β, leading to a reduction in
inflammation and the fibrotic process in a dose-dependent manner
[95]. Vallon et al. in 2013 reported that empagliflozin attenuated dia-
betes-induced renal injuries by amelioration of inflammation and fi-
brosis, probably secondary to lowering glucose levels [96]. Thus, pre-
vention of inflammation and fibrotic events are other beneficial
renoprotective effects of SGLT2i [96].
5.6. Reduction in plasma uric acid levels
It has been proposed that high plasma levels of uric acid (PUA)
might be a risk factor and/or predictor for renal insufficiency [97];
however, this hypothesis is still debatable. An elevated level of PUA
independently predicts the development of CKDs and is associated with
the progression towards renal failure [97]. Therefore, some therapeutic
strategies in CKDs are based upon lowering circulating levels of PUA
and inducing its urinary excretion [97]. SGLT2is markedly reduce PUA
by stimulation of its excretion in urine [98]. SGLT2is ameliorate PUA
via altering tubular transport of uric acid and/or inhibition of GLUT9
(glucose transporter 9, also known as SLC2A9 [Solute carrier family 2,
facilitated glucose transporter member 9]) located at the apical mem-
brane of collecting ducts [98,99]. These beneficial effects of SGLT2i are
related to glycosuria and, so, these agents increase uric acid excretion in
a dose-dependent manner [98,100].
Davies et al in 2015 found that SGLT2 inhibition by canagliflozin
attenuated PUA in T2D [101]. Zhao et al in 2018 reported that da-
pagliflozin decreased PUA in a dose-dependent manner [100]. Xin et al
in 2018 confirmed that SGLT2 inhibition by canagliflozin, dapagliflozin
or empagliflozin is associated with higher uric acid urinary excretion
[102]. Further evidence supports the concept that SGLT2i agents have
renoprotective outcomes via lowering PUA [103–105].
5.7. Possible reduction of RAS activation
Hyperactivation of RAS is associated with hemodynamic variations
and is present in most types of CKDs [106]. In many cases of renal
insufficiency, there is a high level of RAS activity and, therefore, many
therapeutic protocols have focused upon the modulation of RAS acti-
vation as a main target [106–108]. Activation of RAS is associated with
such pathophysiological outcomes in kidneys as fibrosis, BP elevation
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and apoptosis and therefore RAS blocking agents are now considered as
a central pillar of CKD prevention/treatment [109]. It has been sug-
gested that SGLT2 inhibition may modulate RAS activity [106]. Shin
et al in 2016 demonstrated that SGLT2i ameliorates intrarenal and
systemic RAS activity [106]. However, this finding is inconsistent with
previous studies. In this regard, Yoshimoto et al in 2017 reported that
SGLT2i therapy in T2D patients is not accompanied by RAS activation
[110]. Also, Li et al in 2018 demonstrated that daily treatment with a
selective SGLT2 inhibitor of TA-1887 for 10 weeks did not activate
either systemic or intrarenal RAS in dysfunctional kidneys [111]. Thus,
although SGLT2i therapy alters renal tubular Na+ handling, it does not
induce RAS activation [110]. However, there are a few reports sug-
gesting that SGLT2 inhibition increases RAS mediators such as renin,
angiotensin II and aldosterone, probably secondary to volume depletion
and activation of compensative mechanisms [112,113]. Hence, the
possible effect of SGLT2 inhibitors on RAS activation is uncertain and
requires further investigation.
5.8. Reduction in natriuretic peptides level
Atrial natriuretic peptide (ANP) is a biologic protein with hormonal
properties that is released by the cardiac atria and induces volume re-
duction by a urinary natriuresis process; it, therefore, plays an im-
portant role in cardio-renal homeostasis as well as in vascular phy-
siology [114–116]. Although some clinical trials have suggested that
low dose ANP infusion protects against renal dysfunction [117], several
in vitro and in vivo studies have demonstrated that elevation of ANP
plasma levels are a marker of renal dysfunction as occurs in CKDs
[118–120]. Ogawa et al in 2015 reported that the age-dependent in-
crease in ANP levels is closely correlated to CKD development in Ja-
panese patients with progressive renal dysfunction [118]. In addition,
other types of natriuretic peptides, such as brain derived peptides
(BNP), may be involved in the progression of CKDs [121].
SGLT2 inhibition lowers the ANP plasma level [122]. Wang et al in
2016 found that SGLT2 inhibitors ameliorated ANP secretion in newly
diagnosed T2D patients [122]. Januzzi et al in 2017 reported that
SGLT2i by canagliflozin delayed the elevation of BNP in older patients
with T2D [123]. Moreover, Yanai et al in 2018 established that SGLT2
inhibition improved renal function via a reduction in brain-derived
natriuretic peptide [121]. However, the reported beneficial role of low
dose administration of natriuretic peptides [117] is unclear and pre-
mature in terms of renal function and requires further investigation.
5.9. Other possible mechanisms
There are other suggested pathways that may be involved in the
renoprotective effects of SGLT2is, such as inhibition of sympathetic
hyperactivation [124], increase in glucagon release [125], alteration of
mitochondrial morphology [126], elevation of hematocrit [127], im-
provement of tubulointerstitial hypoxia [127], and albuminuria-low-
ering effect [42]. However, these mechanisms are still uncertain and
further evaluation is needed.
6. Clinical trials
Beyond experimental data, we have also strong clinical evidences
indicating the renoprotective roles of SGLT2i in diabetic and non-dia-
betic patients (Table 2). Large clinical trials as, CANVAS, EMPA-REG,
DELIGHT, and CREDENCE, have emphasized the potent renoprotective
effects of SGLT2is via aforementioned molecular mechanisms in pa-
tients with kidney failure [42,68,128–131]. Recently, CREDENCE trial
reported that SGLT2i decreases the risk of dialysis, transplantation, or a
sustained reduction in the eGFR in patients with type 2 diabetes and
nephropathy (eGFR of 30 < 90ml/min/1.73 m2) (Perkovic 2019).
CANVAS study found a beneficial effect of SGLT2i with respect to the
progression of albuminuria and the composite outcome of a sustained
reduction in the eGFR, the need for renal-replacement therapy, or death
from renal causes in patients with type 2 diabetes [128]. Furthermore,
CANVAS Program, in a prespecified exploratory analysis, supported the
renoprotective effect of SGLT2i by decreasing the risk of sustained loss
of kidney function, attenuated eGFR delcline, and reduction in albu-
minuria in patients with type 2 diabetes [129]. EMPA-REG OUTCOME
trial SGLT2i showed a significant risk reduction of incident or wor-
sening nephropathy, progression to macroalbuminuria, and the initia-
tion of renal-replacement therapy in patients with type 2 diabetes and
an eGFR of at least 30ml/min/1.73 m2 [69]. Also, DELIGHT study
revealed that SGLT2i slows the progression of kidney disease through
the albuminuria-lowering effect in patients with type 2 diabetes and
moderate-to-severe chronic kidney disease [131]. Thus, these clinical
trials have clearly confirmed the previous experimental evidences and
demonstrated that SGLT2 inhibition by commonly used drugs markedly
improve renal function via several molecular pathways such as read-
justment in glycemic profile; which in turn prevent of further patho-
physiologic mechanisms as oxidative damages, inflammation, apoptotic
and fibrotic processes; in patients with dysfunctional kidneys. Also,
these clinical evidences have shown other renoprotective effects of
SGLT2i by lowering the body weight, reduction in albuminuria, reg-
ulating urinary albumin/creatinine ratio and improvement in renal
cells’ morphology and lower histological damages leading to improved
eGFR in evaluated populations. It is important to note that SGLT2i have
the potential to induce renal protection by lowering intraglomerular
pressure and glomerular hyperfiltration beyond glucose control. How-
ever, more clinical investigations are still needed to fully understanding
the renoprotecting outcomes of these drugs in humans along with
Table 2
The major clinical studies addressing the renoprotective effects of SGLT2 inhibitors.
Clinical Trials Used Drug(s) Total Population Outcome of SGLT2i Therapy Ref.
EMPA-REG OUTCOME trial (NCT01131676) Empagliflozin 7020 Lower rate of cardiovascular death or hospitalization [132]
EMPA-REG OUTCOME trial (NCT01131676) Empagliflozin 7020 Slows progression of kidney disease [130]
CANVAS-R (NCT01989754) Canagliflozin 10,142 Lower risk of cardiovascular events, reduction in albuminuria and eGFR, and death
from renal causes
[128,129]
– Dapagliflozin 282 Reduction in glycaemic parameters and body weight [133]
– Canagliflozin 2313 Reduction in serum uric acid levels [101]
– Canagliflozin 1450 Slows the progression of CKD, reduces albuminuria and eGFR [134]
– Dapagliflozin 62 Improvement of UACR, uNAG, and kidney morphology, reduction in body fat mass [135]
ClinicalTrials.gov (NCT00680745) Dapagliflozin 597 Improved glycemic control and reduced body weight [136]
DECLARE (NCT01730534) Dapagliflozin 17160 Lower rate of cardiovascular death or hospitalization [137]
CREDENCE (NCT02065791) Canagliflozin 4401 Lower rate of end-stage kidney disease or renal or cardiovascular death [42]
VERTIS (NCT01986881) Ertugliflozin About of 8000 In progress –
EMPA-KIDNEY (NCT03594110) Empagliflozin 5000 In progress –
Dapa-CKD (NCT03036150) Dapagliflozin 4000 In progress –
(CKD= chronic kidney disease; eGFR= estimated glomerular filtration rate; UACR=urinary albumin/creatinine ratio; uNAG=urine N-acetyl-β-glucosaminidase).
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recognizing the exact involved molecular mechanisms as previously
suggested by experimental studies. In Table 2, we present the major
clinical studies reporting the renoprotective effects of SGLT2i.
7. Conclusion
Diabetes-induced kidney disease is the major precipitating cause of
renal replacement therapy worldwide. Therefore, protection of the
kidneys in diabetic patients is critically important. Beyond the hy-
poglycemic effects, SGLT2 inhibition has renoprotective properties.
SGLT2is may protect against renal failure via at least eight molecular
mechanisms, being the effects on hyperglycemia and hypertension the
most important, owing to the key role of these conditions in the pa-
thogenesis of DN. The knowledge relative to the mechanisms implicated
in the SGLT2i off-targets effects is progressively increasing, thus ex-
plaining the benefits reported by the large clinical trials for this class of
hypoglycemic drugs.
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